5-Fluorouracil (NSC-19893), DTIC (NSC-45388), BCNU (NSC-409962), and vincristine (NSC-67574) in advanced colorectal carcinoma.
Thirty-three patients with advanced colorectal carcinoma were treated with 5-day courses of 5-fluorouracil (10 mg/kg/day, iv, Days 1-5), DTIC (3 mg/kg/day, iv, Days 1 and 2), BCNU (1.5 mg/kg/day, iv, Day 1 only), and vincristine (0.025 mg/kg/day, iv, Day 1 only) at 5-week intervals. One patient achieved CR and six patients achieved PRs. Five of ten patients treated within 8 weeks after detection of advanced cancer had CR or PR (P = 0.02). After most courses toxicity was moderate, although it necessitated a change to another regimen for one patient. One patient refused further cancer chemotherapy and one patient died due to severe bone-marrow toxicity.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002330:Carmustine / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003606:Dacarbazine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D012004:Rectal Neoplasms / Q000188:drug therapy*; D012075:Remission, Spontaneous; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014750:Vincristine; D003606:Dacarbazine; D005472:Fluorouracil; D002330:Carmustine